Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular Neovascularization.

Wojnarowicz PM, Lima E Silva R, Ohnaka M, Lee SB, Chin Y, Kulukian A, Chang SH, Desai B, Garcia Escolano M, Shah R, Garcia-Cao M, Xu S, Kadam R, Goldgur Y, Miller MA, Ouerfelli O, Yang G, Arakawa T, Albanese SK, Garland WA, Stoller G, Chaudhary J, Norton L, Soni RK, Philip J, Hendrickson RC, Iavarone A, Dannenberg AJ, Chodera JD, Pavletich N, Lasorella A, Campochiaro PA, Benezra R.

Cell Rep. 2019 Oct 1;29(1):62-75.e7. doi: 10.1016/j.celrep.2019.08.073.

2.

Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization.

Kim J, Lima E Silva R, Shmueli RB, Mirando AC, Tzeng SY, Pandey NB, Ben-Akiva E, Popel AS, Campochiaro PA, Green JJ.

Acta Biomater. 2019 Jul 30. pii: S1742-7061(19)30543-4. doi: 10.1016/j.actbio.2019.07.054. [Epub ahead of print]

PMID:
31374338
3.

Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection.

Zhang Y, Bazzazi H, Lima E Silva R, Pandey NB, Green JJ, Campochiaro PA, Popel AS.

Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):5266-5276. doi: 10.1167/iovs.17-23632.

4.

Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature.

Shen J, Frye M, Lee BL, Reinardy JL, McClung JM, Ding K, Kojima M, Xia H, Seidel C, Lima e Silva R, Dong A, Hackett SF, Wang J, Howard BW, Vestweber D, Kontos CD, Peters KG, Campochiaro PA.

J Clin Invest. 2014 Oct;124(10):4564-76. doi: 10.1172/JCI74527. Epub 2014 Sep 2.

5.

Sustained delivery of a HIF-1 antagonist for ocular neovascularization.

Iwase T, Fu J, Yoshida T, Muramatsu D, Miki A, Hashida N, Lu L, Oveson B, Lima e Silva R, Seidel C, Yang M, Connelly S, Shen J, Han B, Wu M, Semenza GL, Hanes J, Campochiaro PA.

J Control Release. 2013 Dec 28;172(3):625-33. doi: 10.1016/j.jconrel.2013.10.008. Epub 2013 Oct 12.

6.

Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide.

Shmueli RB, Ohnaka M, Miki A, Pandey NB, Lima e Silva R, Koskimaki JE, Kim J, Popel AS, Campochiaro PA, Green JJ.

Biomaterials. 2013 Oct;34(30):7544-51. doi: 10.1016/j.biomaterials.2013.06.044. Epub 2013 Jul 10.

7.

Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit.

Iwase T, Oveson BC, Hashida N, Lima e Silva R, Shen J, Krauss AH, Gale DC, Adamson P, Campochiaro PA.

Invest Ophthalmol Vis Sci. 2013 Jan 21;54(1):503-11. doi: 10.1167/iovs.12-10473.

8.

Agents that bind annexin A2 suppress ocular neovascularization.

Lima e Silva R, Shen J, Gong YY, Seidel CP, Hackett SF, Kesavan K, Jacoby DB, Campochiaro PA.

J Cell Physiol. 2010 Nov;225(3):855-64. doi: 10.1002/jcp.22296.

9.

Mecamylamine suppresses Basal and nicotine-stimulated choroidal neovascularization.

Kiuchi K, Matsuoka M, Wu JC, Lima e Silva R, Kengatharan M, Verghese M, Ueno S, Yokoi K, Khu NH, Cooke JP, Campochiaro PA.

Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1705-11. doi: 10.1167/iovs.07-0089.

10.

The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization.

Lima e Silva R, Shen J, Hackett SF, Kachi S, Akiyama H, Kiuchi K, Yokoi K, Hatara MC, Lauer T, Aslam S, Gong YY, Xiao WH, Khu NH, Thut C, Campochiaro PA.

FASEB J. 2007 Oct;21(12):3219-30. Epub 2007 May 23.

PMID:
17522382
11.

Trans-scleral delivery of polyamine analogs for ocular neovascularization.

Lima e Silva R, Kachi S, Akiyama H, Shen J, Hatara MC, Aslam S, Gong YY, Khu NH, Lauer TW, Hackett SF, Marton LJ, Campochiaro PA.

Exp Eye Res. 2006 Nov;83(5):1260-7. Epub 2006 Sep 6.

PMID:
16950258
12.

Recombinant non-collagenous domain of alpha2(IV) collagen causes involution of choroidal neovascularization by inducing apoptosis.

Lima E Silva R, Kachi S, Akiyama H, Shen J, Aslam S, Yuan Gong Y, Khu NH, Hatara MC, Boutaud A, Peterson R, Campochiaro PA.

J Cell Physiol. 2006 Jul;208(1):161-6.

PMID:
16557520
13.

Suppression and regression of choroidal neovascularization by polyamine analogues.

Lima e Silva R, Saishin Y, Saishin Y, Akiyama H, Kachi S, Aslam S, Rogers B, Deering T, Gong YY, Hackett SF, Lai H, Frydman BJ, Valasinas A, Marton LJ, Campochiaro PA.

Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3323-30.

PMID:
16123436
14.

VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.

Saishin Y, Saishin Y, Takahashi K, Lima e Silva R, Hylton D, Rudge JS, Wiegand SJ, Campochiaro PA.

J Cell Physiol. 2003 May;195(2):241-8.

PMID:
12652651
15.

Effect in vitro of cyclic nucleotides-elevating agents on nitric oxide production by human granulocytes from type 2-diabetic patients.

Nogueira-Machado JA, Lima E Silva FC, Lima E Silva R, Medina LO, Costa DC, Chaves MM.

Diabetes Metab. 2002 Feb;28(1):45-50.

PMID:
11938028
16.

Increase of reactive oxygen (ROS) and nitrogen (RNS) species generated by phagocyting granulocytes related to age.

Martins Chaves M, Rocha-Vieira E, Pereira dos Reis A, de Lima e Silva R, Gerzstein NC, Nogueira-Machado JA.

Mech Ageing Dev. 2000 Oct 20;119(1-2):1-8.

PMID:
11040396
17.

Host defenses in the aged: evaluation of the balance between oxidizing species generation and reducing power in phagocyting human granulocytes.

Chaves MM, Rocha-Vieira E, de Lima e Silva R, Pereira dos Reis A, Nogueira-Machado JA.

Mech Ageing Dev. 1998 Aug 1;104(1):103-9.

PMID:
9751435

Supplemental Content

Loading ...
Support Center